Results 21 to 30 of about 1,056 (174)

Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysis [PDF]

Journal of Comparative Effectiveness Research
Background: Atopic dermatitis (AD) is a chronic and burdensome condition that causes intense itching and painful skin lesions and affects around 10% of adults and adolescents across the US.
Reece Grindley, Linnea Houde, Aseel Bin Sawad, Sanjeev Balu, Shannon Schneider   +4 more
doaj   +2 more sources

The State of the Art in Chronic Prurigo Nodularis [PDF]

Dermatology and Therapy
Chronic prurigo nodularis (CPN) is a highly burdensome chronic inflammatory dermatosis characterized by intensely pruritic papulonodular lesions that may persist for years.
Esther Serra-Baldrich, Ángeles Flórez, Marc Julià Manresa, Francisco Javier Ortiz de Frutos, José-Juan Pereyra-Rodriguez, Bibiana Pérez, Ignasi Figueras   +6 more
doaj   +2 more sources

Comparative efficacy of pediatric atopic dermatitis treatments: a network meta-analysis highlighting dupilumab and pimecrolimus for SCORAD and EASI improvement [PDF]

Frontiers in Immunology
BackgroundAtopic Dermatitis (AD) in children is a common chronic skin condition characterized by dry, itchy and inflamed skin. Various treatments have been applied in the management of AD in children, but the differences in efficacy of different ...
Liu Yang, Ruixue Hu, Yueyuan Wang, Yuanyuan He   +3 more
doaj   +2 more sources

Real-world Clinical Efficacy and Patient-reported Treatment Satisfaction of Nemolizumab Treatment in Prurigo Nodularis [PDF]

Acta Dermato-Venereologica
Yoshihito Mima, Masako Yamamoto, Ken Iozumi   +2 more
doaj   +2 more sources

Bridging the Gap in Chronic Prurigo Care: Evidence-Based Diagnostic and Therapeutic Recommendations from a Delphi Consensus Panel [PDF]

Dermatology and Therapy
Objective Chronic prurigo (CPG) is a chronic neuroinflammatory skin disease characterized by persistent itch, repeated scratching, and the presence of multiple skin lesions.
Pedro Mendes-Bastos, Inês Lobo, Gilberto Pires da Rosa, Rita Pimenta, Margarida Gonçalo, Delphi panel   +5 more
doaj   +2 more sources

A case of concurrent exacerbation of manifestations and asthma after the initiation of nemolizumab treatment for atopic dermatitis

JAAD Case Reports
Yoshimasa Nobeyama, Yozo Ishiuji
exaly   +3 more sources

IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Hepatology, EarlyView., 2022
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen‐Chieh Chuang, Julie Lin, Wen‐Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris V. Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin   +20 more
wiley   +1 more source

Dramatic Improvement of Treatment-Refractory Prurigo Nodularis Following Initiation of Semaglutide: A Case Report [PDF]

Clinical, Cosmetic and Investigational Dermatology
Anne-Claire FougerousseDermatology Department, Military Teaching Hospital Begin, Saint Mandé, FranceCorrespondence: Anne-Claire Fougerousse, Dermatology Department, Military Teaching Hospital Begin, 69 Avenue de Paris, Saint Mandé, 94160, France, Tel +33
Fougerousse AC
doaj   +2 more sources

Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial

Dermatology and Therapy, 2023
Introduction Atopic dermatitis (AD), with its signs and symptoms of pruritus, dryness, and erythema, severely reduces the quality of life (QOL) of affected patients.
Kenji Kabashima, Takayo Matsumura, Hiroshi Komazaki, Makoto Kawashima, The Nemolizumab-JP01 Study Group   +4 more
doaj   +1 more source

Nemolizumab: un innovador tratamiento biológico para el control de la interleuquina 31 (IL-31) clave en la dermatitis atópica y el prurigo nodular

Actas Dermo-Sifiliográficas, 2022
Resumen: La citoquina IL-31 es una neurocitoquina que estimula las neuronas sensoriales relacionadas con el picor, contribuye a la inflamación, la disfunción y remodelación de la barrera epidérmica. Al interrelacionar los sistemas inmunológico y nervioso
E. Serra-Baldrich, L.F. Santamaría-Babí, J. Francisco Silvestre   +2 more
doaj   +1 more source